Looking at the filing, I need to identify key financial figures from the substantive content. The filing text provided is primarily the cover page, table of contents, and forward-looking statements section. Let me extract what I can confirm from the source text. Key confirmed facts: - Form 10-Q for quarterly period ended September 30, 2026 - Filed November 19, 2026 - Company: Rapid Micro Biosystems, Inc. - NASDAQ:RPID (Nasdaq Capital Market) - 46,342,785 shares of Class A common stock outstanding as of November 13, 2026 - 4,499,529 shares of Class B common stock outstanding as of November 13, 2026 - Merger Agreement entered November 16, 2026 with Merck KGaA, Darmstadt, Germany - Purchaser: EMD Holdings NewCo II, Inc., wholly-owned subsidiary of Merck KGaA - Cash tender offer at $0.75 per share for all Class A and Class B common stock - Nasdaq Capital Market minimum bid price compliance concern mentioned - Trinity Capital Inc. debt facility mentioned - Company classified as non-accelerated filer, smaller reporting company, emerging growth company

Rapid Micro Biosystems, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a pending cash tender offer by a Merck KGaA subsidiary at $0.75 per share and reporting 46,342,785 shares of Class A common stock outstanding as of November 13, 2026.

Key Highlights

  • Merger Agreement signed November 16, 2026: The company entered into an Agreement and Plan of Merger with Merck KGaA, Darmstadt, Germany and its wholly-owned subsidiary EMD Holdings NewCo II, Inc. as Purchaser.
  • Tender offer price of $0.75 per share: The Purchaser will commence a cash tender offer to acquire all issued and outstanding shares of Class A and Class B common stock at $0.75 per share.
  • Class A shares outstanding: As of November 13, 2026, there were 46,342,785 shares of Class A common stock, par value $0.01, outstanding.
  • Class B shares outstanding: As of November 13, 2026, there were 4,499,529 shares of Class B common stock, par value $0.01, outstanding.
  • Nasdaq listing compliance risk noted: The company disclosed uncertainty regarding its ability to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
  • Going concern uncertainty referenced: The filing identifies the company's ability to continue as a going concern as a forward-looking consideration subject to multiple risk factors.

Rapid Micro Biosystems Reports Pending Merck KGaA Acquisition in Q3 2026 Filing

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) filed its Form 10-Q for the quarterly period ended September 30, 2026 on November 19, 2026. The filing's most prominent disclosure concerns a Merger Agreement the company entered into on November 16, 2026 with Merck KGaA, Darmstadt, Germany, acting as Parent, and EMD Holdings NewCo II, Inc., described as a wholly-owned subsidiary of Parent and designated as Purchaser. According to the filing, Purchaser will commence a cash tender offer to acquire all issued and outstanding shares of the company's Class A common stock, $0.01 par value per share, and Class B common stock, $0.01 par value per share, at a price of $0.75 per share.

The filing notes that consummation of the transaction is subject to conditions, including that "there shall have been validly tendered (and not validly withdrawn) that number of shares of Class A common stock satisfying the minimum threshold specified in the tender offer." The company also disclosed risks related to retaining key personnel, maintaining relationships with business partners and customers, and responding to competitive pressures during the pendency of the transaction. As of November 13, 2026, the company reported 46,342,785 shares of Class A common stock and 4,499,529 shares of Class B common stock outstanding.

The filing also references the company's existing debt facility with Trinity Capital Inc. and raises the question of its ability to continue as a going concern, noting that future funding requirements may be affected by market uptake of its Growth Direct platform and systems. The company disclosed that it is working to regain compliance with the Nasdaq Capital Market minimum bid price requirement for continued listing. Rapid Micro Biosystems is classified in the filing as a non-accelerated filer, a smaller reporting company, and an emerging growth company. The forward-looking statements in the filing are the company's own and subject to its cautionary language.

What Was Disclosed

Rapid Micro Biosystems filed its Q3 2026 Form 10-Q, disclosing a November 16, 2026 Merger Agreement with Merck KGaA under which EMD Holdings NewCo II, Inc. will launch a cash tender offer for all outstanding Class A and Class B common stock at $0.75 per share, subject to specified conditions.